Literature DB >> 2224850

In vitro migration of lymphocytes through collagen matrix: arrested locomotion in tumor-infiltrating lymphocytes.

K G Applegate1, C M Balch, N R Pellis.   

Abstract

Antitumor immunity requires (a) extravasation of lymphocytes from the blood stream to interstitium, (b) locomotion through extracellular matrix to the site of the tumor, (c) effector cell recognition of the tumor target with cell/cell contact and binding of adhesion receptors, (d) T-cell receptor binding to histocompatibility and tumor antigens, and (e) tumor cell lysis. We hypothesize that the tumor microenvironment inhibits lymphocyte locomotion through extracellular matrix as one mechanism by which tumors may avert host defense. Lymphocyte locomotion was investigated in vitro using a three-dimensional collagen gel model. Fresh tumor-infiltrating lymphocytes (TIL) were obtained by enzymatic digestion of melanomas and renal cell carcinoma, and mononuclear cells were isolated by discontinuous Ficoll-Hypaque gradient. The lymphocytes were analyzed for motility from a point of origin between basal and overlay layers of collagen gel. Results showed that TIL migration was almost completely inhibited, compared with migration of normal and cancer patient peripheral blood leukocytes and lymphocytes from lymph nodes. Short-term (24-h) exposure of lymphocytes to cytokines during the assay in the collagen gel matrix had no effect on locomotor ability. Long-term (19, 30, or 35 days) culture of TIL in 200 units/ml of interleukin 2 reinstated locomotor ability. Short-term exposure of any of the lymphocyte populations to interleukin 1-alpha, interleukin 1-beta, interleukin 2, interleukin 3, interleukin 4, alpha-interferon, or gamma-interferon had no effect on migration. Thus, TIL display a uniquely arrested ability to locomote through collagen gel. Inhibition of the locomotion of infiltrating effector cells is possibly a mechanism by which the tumor evades the host immune system.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2224850

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

1.  Changes in gravity inhibit lymphocyte locomotion through type I collagen.

Authors:  N R Pellis; T J Goodwin; D Risin; B W McIntyre; R P Pizzini; D Cooper; T L Baker; G F Spaulding
Journal:  In Vitro Cell Dev Biol Anim       Date:  1997-05       Impact factor: 2.416

2.  Migration of Cytotoxic T Lymphocytes in 3D Collagen Matrices.

Authors:  Zeinab Sadjadi; Renping Zhao; Markus Hoth; Bin Qu; Heiko Rieger
Journal:  Biophys J       Date:  2020-12-01       Impact factor: 4.033

Review 3.  Cellular immunotherapy: antigen recognition is just the beginning.

Authors:  Daniel S Chen; Mark M Davis
Journal:  Springer Semin Immunopathol       Date:  2005-04-16

Review 4.  Tumor-infiltrating lymphocytes: their phenotype, functions and clinical use.

Authors:  T L Whiteside; G Parmiani
Journal:  Cancer Immunol Immunother       Date:  1994-07       Impact factor: 6.968

5.  Reduced expression of distinct T-cell CD molecules by collagenase/DNase treatment.

Authors:  W M Mulder; H Koenen; A J van de Muysenberg; E Bloemena; J Wagstaff; R J Scheper
Journal:  Cancer Immunol Immunother       Date:  1994-04       Impact factor: 6.968

6.  Tumor-associated lymphocytes (TAL) are competent to produce higher levels of cytokines in neoplastic pleural and peritoneal effusions than those found in sera and are able to release into culture higher levels of IL-2 and IL-6 than those released by PBMC.

Authors:  G Mantovani; A Macciò; R Versace; M Pisano; P Lai; S Esu; M Ghiani; D Dessì; E Turnu; M C Santona
Journal:  J Mol Med (Berl)       Date:  1995-08       Impact factor: 4.599

7.  Impairment of lymphocyte locomotion in the tumor microenvironment and the effect of systemic immunotherapy with liposome-encapsulated muramyl-tripeptide-phosphatidylethanolamine.

Authors:  D Risin; E S Kleinerman; Y Umezu; R P Pizzini; C M Balch; N R Pellis
Journal:  Cancer Immunol Immunother       Date:  1995-01       Impact factor: 6.968

8.  Local antitumour treatment in carcinoma patients with bispecific-monoclonal-antibody-redirected T cells.

Authors:  B J Kroesen; A ter Haar; H Spakman; P Willemse; D T Sleijfer; E G de Vries; N H Mulder; H H Berendsen; P C Limburg; T H The
Journal:  Cancer Immunol Immunother       Date:  1993-11       Impact factor: 6.968

9.  The postoperative neutrophil-to-lymphocyte ratio and changes in this ratio predict survival after the complete resection of stage I non-small cell lung cancer.

Authors:  Feng Jin; Anqin Han; Fang Shi; Li Kong; Jinming Yu
Journal:  Onco Targets Ther       Date:  2016-10-21       Impact factor: 4.147

10.  Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells.

Authors:  S Singh; S R Ross; M Acena; D A Rowley; H Schreiber
Journal:  J Exp Med       Date:  1992-01-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.